Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "DoP"

527 News Found

Lupin launches Droxidopa capsules in the US
Drug Approval | September 29, 2021

Lupin launches Droxidopa capsules in the US

Droxidopa capsules, 100 mg, 200 mg, and 300 mg is a generic equivalent of Northera capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA


Digital adoption in healthcare will see exponential growth: Wipro GE study
Healthcare | September 03, 2021

Digital adoption in healthcare will see exponential growth: Wipro GE study

Key trends indicate that AI-based solutions, cloud-based healthcare solutions and digital transformations will be the key in the years to come.


New gen pharma leaders gear up to adopt digitalization, data analytics and customized R&D
Digitisation | May 27, 2021

New gen pharma leaders gear up to adopt digitalization, data analytics and customized R&D

The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.


Pharma 4.0: Pandemic pushed reluctant pharma companies to adopt advanced technologies
News | March 04, 2021

Pharma 4.0: Pandemic pushed reluctant pharma companies to adopt advanced technologies

Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.


Zydus Cadila receives final approval from USFDA for Droxidopa capsules
News | February 20, 2021

Zydus Cadila receives final approval from USFDA for Droxidopa capsules

It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.


Lupin receives approval for Droxidopa capsules
News | February 20, 2021

Lupin receives approval for Droxidopa capsules

Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness


Lupin receives positive CHMP opinion for biosimilar Ranibizumab
Drug Approval | December 18, 2025

Lupin receives positive CHMP opinion for biosimilar Ranibizumab

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A


Accenture invests in Ryght AI to revolutionize clinical trials
Digitisation | December 16, 2025

Accenture invests in Ryght AI to revolutionize clinical trials

Ryght AI tackles these hurdles with its AI Site Twin platform


Dr. Reddy's Laboratories announces SBTi targets
Sustainability | December 12, 2025

Dr. Reddy's Laboratories announces SBTi targets

Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045